The application of clinical variables and models to predict pulmonary embolism in cancer patients: a comprehensive single cancer center experience

• Published in: Patient preference and adherence 2013-01, Vol.7 (default), p.1111-1116
• Main Authors: Mansour, Asem, Ismael, Yousef, Abunasser, Mahmoud, Hammode, Emad, Turfa, Rim, Abdel-Razeq, Hikmat
• Format: Article
• Language: English
• Subjects: Cancer; Cancer patients; Care and treatment; CT angiography; Diagnosis; Embolisms; Medical diagnosis; Original Research; Prevention; Pulmonary embolism; Pulmonary embolisms; Risk factors; thromboembolism
• ISSN: 1177-889X; 1177-889X
• DOI: 10.2147/PPA.S46372

Prompt diagnosis and treatment of pulmonary embolism (PE) can help reduce its associated morbidity and mortality. Computed tomography chest angiography (CTA) scanning is the most widely used diagnostic modality. In noncancer patients, only 10% of such studies are positive for PE. Clinical variables, individual or in combination, that can predict test positivity are highly needed. All CTAs requested to confirm or exclude a diagnosis of PE in a single comprehensive cancer center were reviewed. In addition to the Wells score, other clinical variables known to increase the risk of PE were analyzed. A total of 778 adult cancer patients were treated at King Hussein Cancer Center (Amman, Jordan) and were included in this study; the majority of patients (64.2%) had stage 4 disease. Overall, 129 (16.6%) patients had positive scans for PE, while alternative diagnoses were made in 308 (39.6%) patients. Cancer stage and anticancer treatment had no impact on positive PE rates. However, Wells criteria classified patients into three risk groups with PE rates of 10.2%, 16.1%, and 62.5% among the patients with low, moderate, and high risk, respectively (P < 0.0001). Duration of cancer diagnosis (12 months) had a significant impact on positive PE studies (22.0% versus 12.4%, respectively, P = 0.007). The rate of positive PE studies in cancer patients is higher than previously reported in noncancer patients. Positivity for PE was higher during the first 12 months of cancer diagnosis and in those with high probability score according to the Wells criteria. Factors like primary tumor stage and anticancer therapy had no significant impact on PE-positive studies.